SecBot SecBot
8-K ·Filed Mar 5, 2026

LXRX

LEXICON PHARMACEUTICALS, INC.
BULLISH
Impact 7/10
Horizonmonths Processed8mo ago SEC0001062822-26-000047
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The substantial cost reductions and influx of cash improve Lexicon's financial runway, reducing near-term dilution risk. Positive regulatory feedback on pilavapadin and progress in pivotal trials for sotagliflozin represent key upcoming catalysts. Traders should monitor enrollment progress in the SONATA-HCM trial and timing of the NDA resubmission for T1D.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.64
T+0 close · Mar 5, 2026 · via day close
Latest settled
+26.22%
T+60 · $2.07
Vs SPY
+14.92%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 5 $1.64entry
  2. T+1 · 9mo ago +4.27%α +5.58% · $1.71
  3. T+5 · 8mo ago +4.88%α +7.12% · $1.72
  4. T+20 · 8mo ago −3.05%α +0.74% · $1.59
  5. T+60 · 6mo ago +26.22%α +14.92% · $2.07
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Lexicon Pharmaceuticals reported Q4 2025 financial results with $5.5 million in revenue, driven by licensing income from Novo Nordisk and INPEFA sales. The company reduced R&D and SG&A expenses significantly year-over-year, cutting its net loss by over half. It also strengthened its balance sheet with $106.7 million in new cash from a stock sale and a milestone payment. Key pipeline progress includes advancing sotagliflozin for HCM and T1D, and preparing pilavapadin for Phase 3 trials in neuropathic pain.

Key Financial Metrics

Revenue
$5.5M
-79.3% YoY
EPS
$-0.04

Key Facts

  • Q4 2025 revenue was $5.5 million, down from $26.6 million in Q4 2024 (primarily due to a $25M upfront payment from Viatris in 2024)
  • Net loss narrowed to $15.5 million in Q4 2025 from $33.8 million in Q4 2024
  • Full-year 2025 net loss was $50.3 million, a 75% improvement from $200.4 million in 2024
  • Received $106.7 million in new cash in February 2026 ($96.7M from stock sale, $10M milestone from Novo Nordisk)
  • Cash, investments, and restricted cash totaled $125.2 million as of December 31, 2025
  • R&D expenses decreased to $11.3 million in Q4 2025 from $26.7 million in Q4 2024
  • SG&A expenses decreased to $8.8 million in Q4 2025 from $32.3 million in Q4 2024
  • SONATA-HCM Phase 3 trial is over 50% enrolled, with completion expected mid-2026
  • Positive End-of-Phase 2 meeting with FDA for pilavapadin supports advancement to Phase 3
  • NDA resubmission for sotagliflozin in T1D targeted for 2026

Financial Impact

Reduced annual net loss by $150.1 million year-over-year and added $106.7 million in new cash, significantly extending runway for clinical development

net losscash positionR&D expensesSG&A expenses

Segment Breakdown

SegmentRevenueGrowth
INPEFA$1.1M-31.9%

Risk Factors

  • Revenue decline reflects absence of large upfront payments; sustainable commercial growth from INPEFA remains limited ($1.1M in Q4)
  • Future milestones and regulatory approvals are not guaranteed, particularly for sotagliflozin in T1D and pilavapadin in Phase 3
  • High reliance on partnership funding (Novo Nordisk) for LX9851 development

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001062822-26-000047
Document: lxrx-20260305.htm0001062822-26-000047
Document: 0001062822-26-000047-index-headers.html0001062822-26-000047
Document: 0001062822-26-000047-index.html0001062822-26-000047
Document: 0001062822-26-000047.txt0001062822-26-000047

Track record

16 reports on LXRX

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +27.52% at T+20 after the Sep 22, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $1.61 to $1.78 Now $1.75 +8.70% ▲ +10.56% +10.25% vs SPY
  2. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  3. Nov 5, 202611d ago Press Release Neutral 4/10 Entry $1.61 to $1.78 Now $1.75 +8.70% ▲ +10.56% +10.25% vs SPY
  4. Sep 22, 20267w ago Institutional Cluster Bearish 4/10 Entry $2.18 to $2.06 Now $1.75 +19.72% ▲ +5.50% +4.78% vs SPY
  5. Aug 6, 202614w ago 8-K Neutral 5/10 No price data
  6. Aug 6, 202614w ago Press Release Neutral 5/10 Entry $2.36 to $2.47 Now $1.75 −25.85% ▲ +4.66% +4.05% vs SPY
  7. Jun 12, 202622w ago Institutional Cluster Bearish 5/10 Entry $1.92 to $1.96 Now $1.75 +8.85% ▼ −2.08% −0.32% vs SPY
  8. Jun 11, 202622w ago Institutional Cluster Neutral 2/10 Entry $1.89 to $1.92 Now $1.75 −7.41% ▲ +1.59% +1.05% vs SPY
  9. May 6, 202627w ago 8-K Neutral 4/10 Entry $1.68 to $1.68 Now $1.75 +4.17% · 0.00% −0.83% vs SPY
  10. Apr 30, 202628w ago 8-K Bearish 6/10 Entry $1.63 to $1.60 Now $1.75 −7.36% ▲ +1.84% +1.50% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 31m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 5, 2026